Botulinum toxin in urology: A review of clinical potential in the treatment of urologic and sexual conditions

Chung, Eric (2015) Botulinum toxin in urology: A review of clinical potential in the treatment of urologic and sexual conditions. Expert Opinion on Biological Therapy, 15 1: 95-102. doi:10.1517/14712598.2015.974543


Author Chung, Eric
Title Botulinum toxin in urology: A review of clinical potential in the treatment of urologic and sexual conditions
Journal name Expert Opinion on Biological Therapy   Check publisher's open access policy
ISSN 1744-7682
1471-2598
Publication date 2015-01-01
Year available 2015
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1517/14712598.2015.974543
Volume 15
Issue 1
Start page 95
End page 102
Total pages 8
Place of publication London, United Kingdom
Publisher Informa Healthcare
Collection year 2016
Language eng
Formatted abstract
Introduction: In recent years, there has been an increased interest in the use of botulinum neurotoxin (BoNT) to treat medical conditions refractory to conventional treatment. The following article provides an overview of the clinical use and efficacy of BoNT in the treatment of various urologic and sexual conditions.

Areas covered: BoNT has been accepted and/or explored as novel treatment for various lower urinary tract and sexual dysfunctions such as overactive bladder/detrusor overactivity (DO), detrusor-sphincter dyssynergia (DSD), benign prostatic hyperplasia, interstitial cystitis/painful bladder syndrome, chronic pelvic pain and more recently premature ejaculation. The following terms ‘botulinum toxin’, ‘BoNT’, ‘botulinum toxin A’, ‘Botox’, ‘Dysport’, ‘Xeomin’, ‘botulinum toxin B’, ‘Myobloc’, ‘OnabotulinumA’, ‘RimabotulinumA’, ‘IncobotulinumA’ and ‘AbobotulinumA’ were used to search several databases including MEDLINE, Pubmed, EMBASE, CINAHL and clinicaltrials.gov for inclusion in this review article. Only English language articles were considered and all studies were limited to BoNT therapy in urological conditions in the adult population.

Expert opinion: BoNT-A has received regulatory approval for use in neurogenic DO and overactive bladder, but its use remains unlicensed in other lower urinary tract conditions such as non-neurogenic lower urinary tract symptoms in men with benign prostatic hyperplasia, bladder pain syndrome and DSD. Published literature shows that BoNT can be effective in carefully selected patient groups, has minimal adverse event profile and is generally well tolerated by many patients. However, many questions remain unanswered and larger scale multi-institutional studies are required to determine the key factors in BoNT treatment success.
Keyword Botulimun
Neurotoxin
OnabotulinumtoxinA
Urology
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 11 Jan 2015, 00:19:28 EST by System User on behalf of Scholarly Communication and Digitisation Service